Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable... ( Common Genetic Variations Predict P...)

Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes

Date:9/22/2008

Common Genetic Variations Predict Patient Response to Novel Beta Blocker

Therapy

TORONTO, Sept. 22 /PRNewswire/ -- Bucindolol, an investigational, pharmacologically unique beta-blocker and mild vasodilator, significantly reduces hospitalization and death among heart failure patients with very favorable genotypes, according to results of a large DNA study presented today as a poster at the annual meeting of the Heart Failure Society of America. Researchers found that common genetic variations can predict which heart failure patients will have the greatest therapeutic response to bucindolol.

ARCA biopharma has submitted a New Drug Application (NDA) for bucindolol to the U.S. Food and Drug Administration for the treatment of chronic heart failure.

"The ability to predict patient response to bucindolol makes it easier for physicians to match the right patient to the right medicine, potentially avoiding months of trial-and-error therapy and helping very sick heart failure patients achieve better outcomes sooner," said Christopher O'Connor, M.D., Director of the Heart Center at Duke University Medical Center and presenter of the study. "This data brings us much closer to realizing the benefits of personalized medicine in heart failure."

The prospectively-designed DNA sub-study included more than 1,000 patients enrolled in the Beta-Blocker Evaluation of Survival Trial (BEST), the largest heart failure mortality trial conducted primarily in the United States. Researchers evaluated therapeutic response to bucindolol among patients with genetic variations, or polymorphisms, in two adrenergic receptors that help regulate cardiac function: beta 1 389 Arg/Gly and alpha 2c 322-325 WT/Del. Researchers identified three distinct genotypes that predict the effect of bucindolol: very favorable (47% of BEST patients), favorable (40%) and unfavorable (13%).

In the study, patients with the very favorable genotype
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
3. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
4. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice

Post Your Comments:

(Date:5/15/2012)... have taken a step toward overcoming a ... that could bring optical advances including ultrapowerful ... researchers have shown how to create the ... previously required, said Alexandra Boltasseva, a Purdue ... engineering. , Using the metals is impractical ...

(Date:5/15/2012)... OrbusNeich today announced that 12-month follow-up data from ... involving the use of the company,s Combo Dual Therapy ... ® paclitaxel-eluting stent. The data were presented by ... Lukaskrankenhaus in Neuss, Germany, at EuroPCR 2012. ... driven target lesion failure (TLF) rate was 8.9% for ...

(Date:5/15/2012)... -- Cardium Therapeutics (NYSE Amex: CXM ... first quarter ended March 31, 2012, and other ... In addition to the announcement ... its goals for 2012, which were outlined in ... advance commercialization of its new Excellagen® advanced, physician-use ...

(Date:5/15/2012)... Butamax™ Advanced Biofuels, LLC announced ... Trademark Office (USPTO) has granted Butamax Patent ... highly efficient engineered pathway for producing isobutanol ... novel microorganisms have been designed using advanced ... (Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO ) ...

[0] New 'metamaterial' practical for optical advances [0] OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up [0] Cardium Presents First Quarter 2012 Financial Results and Recent Developments [0] Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol

... an economic environment where many healthcare providers are ... patients are thriving with help from InstaMed. ... and platform, Prime Health Network has increased patient ... while also improving the patient experience at each ...

... biotechnology company delivering breakthrough therapies in central nervous system ... participating at two upcoming healthcare investor conferences. Dr. Steve ... 2nd Annual BIO Venture Conference on April 1 at ... Boston, MA. On April 9 at 11:30 a.m. PDT, ...

... Shire plc (LSE: SHP, NASDAQ:, SHPGY ), the ... Accounts in respect of the year ended December 31, ... announced unaudited full,year 2008 results, prepared in accordance with ... announcement on February 19,2009. , ...

Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network Accera, Inc. to Present at Upcoming Investor Conferences Publication of Shire plc's Annual Report 2008

(Date:5/21/2012)... team of scientists from the National University of Singapore,s ... discovered how a drug-led compound a compound that ... can deprive cancer cells of energy and stop them ... named BPTES. , This is the first time ... drug-lead compound suppresses tumour formation. , Building on ...

(Date:5/21/2012)... , , , , , ... , , , , , ... thanks to breakthrough research by CSIRO researchers who have supercharged safflower to produce increased amounts... , , ... , , , , , ... , , , , , , , , ...

(Date:5/20/2012)... melody, the male songbird uses a trial-and-error process to mimic ... over again, hundreds of times a day, making subtle changes ... finch, this rigorous training process begins around the age of ... he becomes sexually mature and ready to use his song ... brain must receive and process large quantities of information about ...

Breaking Biology News(10 mins):Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2 Supercharged safflower 2 Supercharged safflower 3 Supercharged safflower 4 Songbirds' learning hub in brain offers insight into motor control 2 Songbirds' learning hub in brain offers insight into motor control 3 Luminex Corporation Reports Second Quarter 2011 Results 19401 1 Luminex Corporation Reports Second Quarter 2011 Results 19401 2 Luminex Corporation Reports Second Quarter 2011 Results 19401 3 Luminex Corporation Reports Second Quarter 2011 Results 19401 4 Luminex Corporation Reports Second Quarter 2011 Results 19401 5 Luminex Corporation Reports Second Quarter 2011 Results 19401 6 Luminex Corporation Reports Second Quarter 2011 Results 19401 7 Luminex Corporation Reports Second Quarter 2011 Results 19401 8 Luminex Corporation Reports Second Quarter 2011 Results 19401 9 NeurogesX Inc Secures 2420 Million Debt Facility 19398 1 NeurogesX Inc Secures 2420 Million Debt Facility 19398 2 NeurogesX Inc Secures 2420 Million Debt Facility 19398 3 NeurogesX Inc Secures 2420 Million Debt Facility 19398 4 As Heart Failure Worsens Word Recall May Suffer Too 84250 1

[0] Novel discovery by NUS scientists paves the way for more effective treatment of cancers [0] Supercharged safflower [0] Songbirds' learning hub in brain offers insight into motor control

... flavanols, the unique compounds found naturally in cocoa, may ... research published in the Neuropsychiatric Disease and Treatment journal. ... flow could impact cognitive behavior, offering future potential for ... a scientific study of healthy, older adults ages 59 ...

... entrepreneurial geneticist Craig Venter sailed around the world on ... ambitious project to use genetics to understand invisible ecological ... jumble of mystery DNA fragments belonging to thousands of ... University of Washington scientist has studied lake mud, which ...

... the sweeping destruction of the 1918 flu pandemic, researchers at ... to the virus from elderly survivors of the original ... long-lasting immunity to such viruses, these antibodies could be effective ... the 1918 flu breaks out in the future. , ...

Other Biology News:Researchers link cocoa flavanols to improved brain blood flow 2 Researchers link cocoa flavanols to improved brain blood flow 3 Cataloguing invisible life: Microbe genome emerges from lake sediment 2 Cataloguing invisible life: Microbe genome emerges from lake sediment 3 1918 flu antibodies resurrected from elderly survivors 2

Researchers link cocoa flavanols to improved brain blood flow Cataloguing invisible life: Microbe genome emerges from lake sediment 1918 flu antibodies resurrected from elderly survivors

... Agencourt offers single pass sequencing ... service is fueled by our high ... 20 million Phred20 bases per day. ... single pass sequencing customers are rapid ...

GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....

...

... calibration, and validation (MCV) plate ... plate used for hands-free startup, ... using the Bio-Plex suspension array ... for use with Bio-Plex Manager ...

Biology Products:

Single Pass DNA Sequencing from Agencourt Bioscience FDA-Submission Quality DNA Sequencing from Seqwright Cytomics FC 500 Series Flow Cytometry Systems from Beckman Coulter Bio-Plex MCV Plate III from Bio-Rad

Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable...( Common Genetic Variations Predict P...)